FUNDAMENTALS · Fundamentals · US Healthcare

Encompass Health (EHC) Fundamentals 2026 — P/E 18.2x, Revenue Analysis | SniperIQ

Encompass Health (EHC) is a US-listed Healthcare company in Medical - Care Facilities with a market capitalization of

1.0B, trading at
10.77 on the NYSE. This SniperIQ fundamentals page covers Encompass Health's valuation (P/E 18.2x, P/B 4.4x), profitability (net margin 10.0%), revenue ($5.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
1.0B
P/E (TTM)18.2x
Net Margin10.0%
Revenue (FY25)$5.9B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Encompass Health's market cap?

Encompass Health (EHC) has a market capitalization of approximately

1.0B, trading at
10.77 on the NYSE. Market cap moves with the live share price.

What is Encompass Health's P/E ratio?

Encompass Health's trailing twelve-month P/E ratio is 18.2x, with a price-to-book (P/B) of 4.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Encompass Health?

Encompass Health runs a net profit margin of 10.0%, a gross margin of 58.8%, and an operating margin of 17.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Encompass Health generate?

Encompass Health reported revenue of $5.9B for fiscal year 2025, with net income of $566M and earnings per share (EPS) of 5.62. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Encompass Health pay a dividend?

Encompass Health offers a trailing dividend yield of about 0.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Encompass Health financially healthy?

Encompass Health carries a debt-to-equity ratio of 1.11x and a current ratio of 1.17x, with a market beta of 0.60. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Encompass Health a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Encompass Health (EHC) the key facts are: market cap

1.0B, P/E 18.2x, revenue $5.9B, 52-week range 92.77-127.99. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Encompass Health's full fundamentals live

Get Encompass Health's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: China National Accord Medicines (000028) fundamentals · Zhejiang CONBA Pharmaceutical (600572) fundamentals · Inner Mongolia Furui Medical Science (300049) fundamentals · Chengdu Olymvax Biopharmaceuticals (688319) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons